The breast cancer med Ibrance has been a shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to lift the whole company.
Pfizer is counting on a new approval for Sutent, its kidney cancer drug, but an FDA advisory panel isn’t so sure.
Buried in OTC remedies like laxatives, fiber and probiotics? That's the question in Allergan and Ironwood's latest Linzess ads.
After years of going it alone in investigating opioid drugmakers, attorneys general across the U.S. are joining forces to drill into painkiller marketing…
After years of being recruited, pro athlete Deion Sanders is doing some recruiting of his own—for Botox.
AbbVie and Roche amped up blockbuster hopes for Venclexta, their blood cancer drug, with data pointing the way to a big new approval.
Finn is creating a platform where pharma clients can build on their emerging goals for corporate social responsibility.
Keytruda's stumble in multiple myeloma has prompted the FDA to halt recruitment in Roche's Tecentriq tests in that cancer.
Sanofi, Regeneron and Amgen, locked in a PCSK9 market battle, are touting the cholesterol drugs' benefits for patients with diabetes.
Samsung Bioepis has taken a big step toward approval for a Herceptin biosim in Europe.